Ibogaine, an Anti-Addictive Drug: Pharmacology and Time to Go Further in Development

Total Page:16

File Type:pdf, Size:1020Kb

Ibogaine, an Anti-Addictive Drug: Pharmacology and Time to Go Further in Development Human & Experimental Toxicology (2008) 27: 181-194 www.het.sagepub.com Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review R Maciulaitls', V KontrimaviÈiüté^••^ FMM BressoUe^ and V Briedis^ 'Department of Basic and Clinical Pharmacology. Kaunas University of Medicine, Lithuania; ^Clinical Pharmacokinetic Laboratory, Faculty of Pharmacy, University Montpellier L France: ''Department of Analytical and Toxicological Chemistry, Kaunas University of Medicine. Lithuania: and '^Department of Pharmaceutical Technology and Social Pharmacy, Kaunas University of Medicine, Lithuania Ibogaine is an Índole alkaloid derived from the bark of physiological and psychological actions of ihogaine are the root of the African shrub Tabernanlhe iboga. Psycho- not completely understood. Ihogaine is rapidly melaho- active properties of ibogaine have been known for dec- lized in the hody in norihogaine. The purpose oí this arti- ades. More recently, based on experimental data from cle was to review data from the literature concerning animals and anectodal reports in human, it has been physicochemical properties, hio-analytical methods, and found that this drug has anti-addictive efFecls. Several pharmacology of ihogaine: this article will he focused on patents were published between 1969 and 1995. The the use of this drug as anti-addictive agent. pharmacology of ihogaine is quite complex, affecting many different neurotransmitter systems simultaneously. Key words; bioanalytical nielhods: iliogaino: noribogaintí; phar- However, Ihe pharmacülogicai targets underlying the marodynamic studies: pharmacokincUcs: safety Introduction will we forget about this novelty in addictive therapy or will we have a finalized development. The development process ofthe medicinal product is The mechanism of action of ibogaine in the treat- a system consisting of many operational aspects ment of drug addiction appears to be distinct from designed to solve certain organizational, scientific, other existing p harm ac o therapeutic approaches. The and regulatory questions.^'^ Ideally one can have a purpose of this article was to review data from the clear view about this system, meet the needs, and literature concerning physicochemical properties, have a product on the market. The real problems bio-analytical methods, and pharmacology of ibo- are the practicalities that hinder implementation of gaine; this article will be focused on the use of this ideal principles and make product failed. Bib- drug as anti-addictive agent. liographical review of ibogaine development might be one of the learning case studies that we can To identify articles for this review, we use learn from others. Ibogaine is one ofthe psychoactive Internet-based Grateful Med to access electronic índole alkaloids naturally occurring in the West Afri- databases: MEDLINE and Currents Contents 1957- can shrub Tabernanthe iboga. The major compo- 2007. We searched, without language limitations, nents of T. iboga root bark extracts are ibogaine for the subject terms "ihogaine", "noribogaine", (approximately 80%). ibogaline (15%), and iboga- "mechanism of action", "quantification", "pharma- mine (up to 5%1. which confirms the complexity of cokinetics", and "pharmacodynamics". We further the extract.^ From the results ofthe preclinical stud- narrowed the search hy using the terms "anti- ies and anecdotal reports from American and Euro- addictive properties", "animals", "healthy volun- pean addict self-help groups, ibogaine could be a teers", and "dependent patients". We then improved promising drug in addiction therapy. Unfortunately, tlie search using the terms "withdrawal signs" and lost opportunities to confirm a positive benefit risk "drug craving". We identified additional citations balance during both preclinical and clinical develop- from the reference sections of articles retrieved and ments as well as losses of financial supports have consulted these articles. We completed this search lead to the stopping of the ibogaine development in using the website "google.com" and the engine the treatment of drug dependence. Future will show "Copernic". the strategy one will obtain and outcome thereof - History [forraspondence to: Dr Françoise Brossolle, PhD, Laboratoire de Ibogaine is a naturally occurring plant Índole alka- Phiirmacocinétique Ciiniquo. Faculté de Pharmacie Montpellier. 15 Avenue Charles Flahaull. B.P. 14491, 34093 Montpellier loid. The root bark of the Apocynaceous shrub Cedex 5, France. Email: [email protected] T. iboga is the most frequently cited source of © 2008 SAGE Publications 10,1177/0960327107087802 Ibogaine, an anti-addictive drug R Maciulaitis, et al. 182 ibogaine. The Iboga tree is the central pillar of the thetically from nicotinamide hy way of a 13 or 14 step Bwiti religion practiced in West-Central Africa, process.^'' although extraction from the iboga root is a mainly Gabon. Cameroon, and the Republic of the simpler metliod for obtaining the compound. Ibogaine Congo, which uses the alkaloid-containing roots of has B melting point of 153 °C and a pK^. of 8,1 in 80% the plant for its psychoactive properties in a number methylcellosolve; its heptano/water partition coeffr- of ceremonies. Ibogaine is also used by indigenous cient of 28 confirms the lipophilicity of the com- peoples in low doses to combat fatigue, hunger, and pound. Recently, a stmctiiral analysis of ibogaino thirst." Other sources of ibogaine are Voacanga and of its main active metabolite, noribogaine (or 12- tbouarsii var. Ortusa.,^ Tahernnfímontana austniUs''', hydroxyibogamino. (6R. 6aS. 7S. 9R)-7-ethyl-6, 6a, 7. and Tabernaemontana orientalis7 Although known 8, 9, 10, 12, 13-octahydro-5H-6, 9-methanopyrido for many centuries for tribes in West Africa, research [l',2':1.2lazepino|4,5-/jlkidol-2-ol. Figure 1), using of ihogaino ¡itarted in late 19th century. The first Fourrier transform-infrared spectroscopy, lD and 2D description of T. iboga is published in 19B5 from spe- nuclear magnetic rnsonanco spectroscopy, and liquid cimens ofthe plant brought to France from Gabon." A chromatography-electrospray mass spectrometry publishfîd description of the ceremonial use of (LG/HSI-MS) has been published.^'' In accordance T. iboga in Gabon appears in 1885." Ibogaine was with the article of Taylor.-^ a fragmentation pattern iji first extracted and crystallized from the T. iboga root LC/ESI-MS is proposed (Figure 2). Ibogaine and nori- in 1901."*"'^ Ibogaine structure has been established bogaint! in solution suffer facile autoxidation under in 1957 through chemical studies,'^ and X-ray crys- light- and heat-exposure giving iboluteine and ibo- tallographic investigations have fixed the configura- chine. and desmethoxyiboluteine and desmetJioxyi- tion ofthe ethyl group.^"* Moreover, ^•'C nuclear mag- bochine, respectively.^'*"^'^ Recently, it has been netic resonance data'^ were reported in comparison shown that at 20 °C with daylight exposure, ibogaine with several iboga similar structures. The total syn- (22.4 ng/mL] and noribogaine (25 ng/niL) showed a thesis of ibogaine and its availability in the form of monoexponential decrease in cfrug concentrations: the racomate was reported in 1966."' the corresponding half-lives were 81,5 min for ibo- The intßrest of ibogaine to contemporary pharma- gaine and 11 min for noribogaine.^'' cology is that this drug possesses anti-addictive properties. Between 1969 and 1995, tlie anti- Analytical methods addictive properties of ibogaine and its use in the Ibogaine was determined in complex mixtures of treatment of heroin, cocaine, amphetamine abuse, T. iboga and in biological matrices (brain homogenate, alcohol, and nicotine dependence, and even some urine, and plasma) by spectrophotometry.^** thin-layer drug abuse have been patented in the United States chromatography,^-' or gas chi'omatography with and in France. A French patent for the psychothera- ñame ionization,^^^"* nitrogen-specific''^ or mass- peutic use of ihogaine at a dosage of 4—5 mg/kg was spoctrometric (electron impact or chemical ioniza- published in 1969.'" US patents have been pub- tion)''^"''^ detection. Most of these methods involved lished by Lotsof for the use of ibogaine in opioid a derivatization procedure. A method for determining withdrawal, dependence on cocaine and other sti- opiate agonists including ibogaine by liquid mulants, alcohol, nicotine, and polysubstance chromatography-atmospheric-pressure chemical- abuse.'^"^^ These patents claim that an oral or rectal ionization mass spectrometry procedure has heen 4-25 mg/kg dose of ibogaine interrupts addictive also described (LC/APCI-MS).^*^' Recently, a high per- drug behavior for a period of 6-36 months. formance liquid cliromatography method with fluo- Chemistry Ibogaine (12-methoxyibogamine. (6R, 6aS, 7S, 9R)-7- ethyl-2-methoxy-6, 6a, 7, 8, 9, 10, 12, 13-octahydro- 5H-6, 9-methanopyrido[l',2':l,2|azepino[4,5-6iindole) has a molecular weight of 310.44 (Figure l). Extrac- tion of ibogaine from T. iboga shrub requires profes- sional training. N4ainly haloalkanes or alcohols were used for extraction. Chromatography was the method of choice for its purification. Extraction of ibogaine R = O H Noribogaïnc from T. iboga root bark using diluted vinegar and R = OCH3 Ibogaine ammonia was described. ' This drug can also he obtained semisynthetically from voacangine-' or syn- Figure 1 Molecular structurefi of ibogaine and noribogaine. [bogaine, an antj-addictive drug R Maciulaitis, ef ai. 183 »o. 122.1 136 Figure
Recommended publications
  • Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A
    1 Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A. Ban By the mid-1990s the pioneering generation in neuropsychopharmacology was fading away. To preserve their legacy the late Oakley Ray (1931-2007), at the time Secretary of the American College of Neuropsychopharmacology (ACNP), generated funds from Solway Pharmaceuticals for the founding of the ACNP-Solway Archives in Neuropsychopharmacology. Ray also arranged for the videotaping of interviews (mainly by their peers) with the pioneers, mostly at annual meetings, to be stored in the archives. Herbert Kleber was interviewed by Andrea Tone, a medical historian at the Annual Meeting of the College held in San Juan, Puerto Rico, on December 7, 2003 (Ban 2011a; Kleber 2011a). The endeavor that was to become known as the “oral history project” is based on 235 videotaped interviews conducted by 66 interviewers with 213 interviewees which, on the basis of their content, were divided and edited into a 10-volume series produced by Thomas A. Ban, in collaboration with nine colleagues who were to become volume editors. One of them, Herbert Kleber, was responsible for the editing of Volume Six, dedicated to Addiction (Kleber 2011b). The series was published by the ACNP with the title “An Oral History of Neuropsychopharmacology Peer Interviews The First Fifty Years” and released at the 50th Anniversary Meeting of the College in 2011 (Ban 2011b). Herbert Daniel Kleber was born January 19, 1934, in Pittsburgh, Pennsylvania. His family’s father’s side was from Vilnius, Lithuania, and the Mother’s side was from Germany. Both families came to the United State during the first decade of the 20th century.
    [Show full text]
  • Chapter 1—— IBOGAINE: a REVIEW
    ——Chapter 1—— IBOGAINE: A REVIEW Kenneth R. Alper Departments of Psychiatry and Neurology New York University School of Medicine New York, NY 10016 I. Introduction, Chemical Properties, and Historical Time Line .................................... A. Introduction............................................................................................................ B. Chemical Structure and Properties ........................................................................ C. Historical Time Line.............................................................................................. II. Mechanisms of Action ................................................................................................. A. Neurotransmitter Activities.................................................................................... B. Discrimination Studies........................................................................................... C. Effects on Neuropeptides....................................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ........................................................................................................... III. Evidence of Efficacy in Animal Models....................................................................... A. Drug Self-Administration ...................................................................................... B. Acute Opioid Withdrawal.....................................................................................
    [Show full text]
  • Central Intelligence Agency (CIA) Freedom of Information Act (FOIA) Case Log October 2000 - April 2002
    Description of document: Central Intelligence Agency (CIA) Freedom of Information Act (FOIA) Case Log October 2000 - April 2002 Requested date: 2002 Release date: 2003 Posted date: 08-February-2021 Source of document: Information and Privacy Coordinator Central Intelligence Agency Washington, DC 20505 Fax: 703-613-3007 Filing a FOIA Records Request Online The governmentattic.org web site (“the site”) is a First Amendment free speech web site and is noncommercial and free to the public. The site and materials made available on the site, such as this file, are for reference only. The governmentattic.org web site and its principals have made every effort to make this information as complete and as accurate as possible, however, there may be mistakes and omissions, both typographical and in content. The governmentattic.org web site and its principals shall have neither liability nor responsibility to any person or entity with respect to any loss or damage caused, or alleged to have been caused, directly or indirectly, by the information provided on the governmentattic.org web site or in this file. The public records published on the site were obtained from government agencies using proper legal channels. Each document is identified as to the source. Any concerns about the contents of the site should be directed to the agency originating the document in question. GovernmentAttic.org is not responsible for the contents of documents published on the website. 1 O ct 2000_30 April 2002 Creation Date Requester Last Name Case Subject 36802.28679 STRANEY TECHNOLOGICAL GROWTH OF INDIA; HONG KONG; CHINA AND WTO 36802.2992 CRAWFORD EIGHT DIFFERENT REQUESTS FOR REPORTS REGARDING CIA EMPLOYEES OR AGENTS 36802.43927 MONTAN EDWARD GRADY PARTIN 36802.44378 TAVAKOLI-NOURI STEPHEN FLACK GUNTHER 36810.54721 BISHOP SCIENCE OF IDENTITY FOUNDATION 36810.55028 KHEMANEY TI LEAF PRODUCTIONS, LTD.
    [Show full text]
  • M a P S • V O L U M E X I I I N U M B E R 2
    m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 1 2 m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 Divine Spark The cover of this MAPS bulletin is an image from visionary artist Alex Grey’s triptych Holy Fire, which was inspired by one of Alex’s early MDMA experiences. We thought it was an appropriate choice to ex- press our emotions at obtaining Institutional Review Board (IRB) approval for Dr. Mithoefer's MAPS-sponsored MDMA/PTSD study (see page 7). The rest of the images on this page and on the back cover are from the 2003 Burning Man Festival, at which MAPS provided psychedelic emergency services. (Article on page 28). In the photo above, members of the Fire Conclave open the festivities at the Burning of the Man, the climax of the week-long festival. The photo below depicts the more somber burning of the Temple of Honor, at which Burning Man participants remember loved ones by leaving notes and tokens inside. As the temple burned, MAPS president Rick Doblin threw in the fire the original copies of the last set of documents about protocol design issues exchanged between MAPS and the IRB. This symbolized his hopes that we would finally move beyond the paperwork of the approval process to the therapeutic work of the study itself.
    [Show full text]
  • The Search for the "Manchurian Candidate" the Cia and Mind Control
    THE SEARCH FOR THE "MANCHURIAN CANDIDATE" THE CIA AND MIND CONTROL John Marks Allen Lane Allen Lane Penguin Books Ltd 17 Grosvenor Gardens London SW1 OBD First published in the U.S.A. by Times Books, a division of Quadrangle/The New York Times Book Co., Inc., and simultaneously in Canada by Fitzhenry & Whiteside Ltd, 1979 First published in Great Britain by Allen Lane 1979 Copyright <£> John Marks, 1979 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner ISBN 07139 12790 jj Printed in Great Britain by f Thomson Litho Ltd, East Kilbride, Scotland J For Barbara and Daniel AUTHOR'S NOTE This book has grown out of the 16,000 pages of documents that the CIA released to me under the Freedom of Information Act. Without these documents, the best investigative reporting in the world could not have produced a book, and the secrets of CIA mind-control work would have remained buried forever, as the men who knew them had always intended. From the documentary base, I was able to expand my knowledge through interviews and readings in the behavioral sciences. Neverthe- less, the final result is not the whole story of the CIA's attack on the mind. Only a few insiders could have written that, and they choose to remain silent. I have done the best I can to make the book as accurate as possible, but I have been hampered by the refusal of most of the principal characters to be interviewed and by the CIA's destruction in 1973 of many of the key docu- ments.
    [Show full text]
  • Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's
    Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease by Amandeep Mann A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Amandeep Mann 2011 Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease Amandeep Mann Doctor of Philosophy, 2011 Graduate Department of Pharmacology and Toxicology University of Toronto Abstract The enzyme CYP2D6 can metabolize many centrally acting drugs and endogenous neural compounds (e.g. catecholamines); it can also inactivate neurotoxins such as 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1,2,3,4-tetrahydroisoquinoline (TIQ) and β- carbolines that have been associated with Parkinson’s disease (PD). CYP2D6 is ideally situated in the brain to inactivate these neurotoxins. The CYP2D6 gene is also highly polymorphic, which leads to large variation in substrate metabolism. Furthermore, CYP2D6 genetically poor metabolizers are known to be at higher risk for developing PD, a risk that increases with exposure to pesticides. Conversely, smokers have a reduced risk for PD and smokers are suggested to have higher brain CYP2D6 levels. Our studies furthered the characterization and involvement of CYP2D6 in neuroprotection against PD. METHODS: We investigated the effects of CYP2D6 inhibition on MPP+-induced cell death in SH-SHY5Y human neuroblastoma cells. We compared levels of brain CYP2D6, measured by western blotting, between human smokers and non-smokers, between African Green monkeys treated with saline or nicotine, and between PD cases and controls. In addition, we assessed changes in human brain CYP2D6 expression with age.
    [Show full text]
  • DOC 0000151875.Pdf
    • , . Ill' -~ ..__ _.,, 5 JlrJ.7 l959 COMPARISON OF THE REACTIONS INDUCED frt PSILOCYBU~ AND LSD-2$ IN ~Wi By Harris Isbell ;··· . ·:· FrOl!l the National Institute ot Mental Health• Addiction Research Center, • u. s. Public Health Service, Lex!ngtonJ Kentucky. 8-r7/ COMPAJt 1 SON OF THE REACT !ONS INDUCED BY PSILOCYBIN AND LSD-2$ IN r~ The use ot certain intoxicating Dr'wshrooma by Indians in ~lex! co has been rev! ewed by Hofma.ll.&"'l .!!, it:. (1958) • V. P. and R. G. Wasson (1957) have reported the way ln which the mushrooms are taken by the Mexican Indians and the hallucinatory experiences occurring following their lngest!on. Hofmann !1-~ (1958a) have described the !dent1fleat!on ot the mushrooms and their successful culture ~ Heim, and b,y Helm and Ca!lleux. Hormann~~ (1958) Isolated a pure compound from the mushrooms which had the eharncter1st1cs of an lndoleamlne and ~1ch contained phosphorus. Later the compound was 1dentlt1ed as o•Phosphoryl-4-hydrox,y-N-dimethyl tryptamine, was synthesized (Hot:mann, 1958; Hofma.'Ul ~ al., 19S8 a. and b) and named ps11oeyb1n. Pre11m1nary studies In man (Hofmann e~ .!?!» ·1958a) showed that · . the compound. ln doses or 4 to 8 mg. Induced an abnormal mental state ~esembl!ng that seen after LSD or mescaline. In animals .. (Cer1ettl 1 1958). psiloc.ybln caused neurovegetative symptoms although 1t had no h!gh degree or act1v1ty on peripheral .... ·- /J-/7{) ---"' Page Z autonomic s~ructures. The autonomic etrects ot psilocybin seemed to be due to~ central sympathetic stimulation. It facilitated spinal reflexes and causea an "arousal" p_a.ttern ln ~~e EEG.
    [Show full text]
  • Hallucinogen May Cure Drug Addictions (PDF)
    <<Back Hallucinogen May Cure Drug Addiction Posted: February 18, 2004 at 8:58 p.m. BAY AREA (KRON) -- Drug addiction has been the plague of modern America. But that could now change forever. What started as a rumor may now actually be an incredible breakthrough in the battle against addictions of all kinds. Ibogaine has a number of strikes against it: It doesn't come from a modern laboratory, but from an ancient plant. It was discovered not by a scientist, but by a heroin addict. It is mildly hallucinogenic and completely illegal in the United States. However, when it comes to curing addiction, a reputable scientist believes ibogaine is nothing short of a miracle. "I didn't believe it when I first heard about ibogaine. I thought it was something that needed to be debunked," admits Dr. Deborah Mash, professor of Neurology and Molecular and Cellular Pharmacology at University of Miami. Dr. Mash is one of the few scientists in the world to study ibogaine, a mild hallucinogen that comes from the root of a shrub found in West Africa and was rumored to have the amazing ability to help drug addicts kick their addiction. "This didn't come from the Salk Institute, this didn't come from the Scripps Institute. This came from a junkie who took a dose to get high himself. So the original observation came from the underground," says Dr. Mash. Observations from this particular underground are not likely to gain the respect of mainstream society, and ibogaine was no exception. That first report came in 1962.
    [Show full text]
  • Interview with Jerry Jaffe
    on-site media transcription services Interviewed by Nancy D. Campbell for the Oral History of Substance Abuse Research project, which was supported by the National Science Foundation; the University of Michigan Substance Abuse Research Center; the College on Problems of Drug Dependence; and Rensselaer Polytechnic Institute. Ideas expressed do not reflect official positions of any of these organizations. Transcripts of the oral histories are held at the Bentley Historical Library, University of Michigan, Ann Arbor. The interview below is reposted with permission of Dr. Jaffe and the Oral History of Substance Abuse Research project. Information on other interviews conducted as part of the Oral History of Substance Abuse Research can be found at http://sitemaker.umich.edu/umsarc/oral_history_interviews. NANCY CAMPBELL SUBJECT: ADDICTION RESEARCH INTERVIEWER: NANCY CAMPBELL INTERVIEWEE: JERRY JAFFE SOURCE FILES: 01 - JERRY JAFFE I.MP3 02 - JERRY JAFFE II.MP3 03 - JERRY JAFFE III.MP3 04 - JERRY JAFFE IV.MP3 05 - JERRY JAFFE V.MP3 LENGTH: 372 MINUTES [BEGIN 01 - JERRY JAFFE I.MP3] NANCY CAMPBELL: How you would characterize the state of knowledge in the field of psychopharmacology when you first entered it? NANCY CAMPBELL/ADDICTION RESEARCH/JERRY JAFFE Page 2 of 187 JERRY JAFFE: Drugs that could treat psychiatric disorders were just beginning to be developed. As I recall, in 1952 chlorpromazine was being promoted only for the treatment of nausea. In a way, I entered the field in the 1950s, when I was an undergraduate at Temple University studying experimental psychology. I had an experiment running rats and testing ways to measure pain thresholds that I thought were better than how other people were doing it.
    [Show full text]
  • Plenary Brochure
    Previous Award Winners Nathan B. Eddy Memorial Award Joseph Cochin Young 1974 • Maurice Seevers Investigator Award Plenary Program 1975 • Harris Isbell 1987 • Michael Bozarth 1976 • Abraham Wikler 1988 • Frank Porreca 1977 • William Martin 1989 • Errol B. De Souza 1978 • Hans Kosterlitz 1990 • Thomas Kosten & 2005 Awards 1979 • E. Leong Way 1991 • Richard Rothman 1980 • Avram Goldstein 1992 • Jeffrey M. Witkin 1981 • Everette May 1993 • Stephen Higgins 1982 • Vincent Dole 1994 • Richard W. Foltin Sunday June 19 • Great Hall, Wyndham Palace Hotel • Orlando, Florida Marie Nyswander 1995 • Warren K. Bickel 1983 • Eric Simon 1996 • Toni Shippenberg 1984 • Raymond Houde 1997 • Lisa H. Gold 1985 • Louis Harris 1998 • S. Stevens Negus 8:30 • Welcome 1986 • Harold Kalant 1999 • Sari Izenwasser Warren K. Bickel, President, CPDD 1987 • Clifton K. Himmelsbach 2000 • Leslie Amass 1988 • Albert Herz Sharon Walsh 8:45 • Report from National Institute on Drug Abuse 1989 • Leo E. Hollister 2001 • S. Barak Caine Nora D. Volkow, Director, NIDA 1990 • Charles Schuster 2002 • Laura Sim-Selley 1991 • Phillip S. Portoghese 2003 • Andrew Coop Akira E. Takemori 2004 • Sandra D. Comer 9:15 • Presentation of the Meritorious Service Award to Ian P. Stolerman 1992 • Joseph V. Brady Introduction by Chris-Ellyn Johanson 1993 • Lee N. Robins J. Michael Morrison Award 1994 • Jerome H. Jaffe 1986 • Edward C. Tocus 9:20 • Presentation of the Media Award to Brian Vastag 1988 • Marvin Snyder 1995 • Herbert D. Kleber Introduction by Marc J. Kaufman 1996 • Griffith Edwards 1990 • Arthur E. Jacobson 1997 • Martin W. Adler 1992 • Hans Halbach 1998 • John W. Lewis 1993 • Beny Primm 9:25 • Presentation of the Joseph Cochin Young Investigator Award to 1999 • Mary Jeanne Kreek 1995 • Jack D.
    [Show full text]
  • And LSD-25 K'an '• • by '9'9( HARRIS ISBELL
    7 ' - 5000/XI 59 LSD 694/PSI 20 i So_uterdruck t, "__ aus ,,Psychopharmacologia", 1. Band, 1. He/t (1959) | S:'. ,, I Ot_bii Springer. Verlag, Berlin. G6ttingen. Heidelberg balm the National Institute of Mental Health, Addiction Research Center, _(_b U.S. Public Health Service, Lexingto_l, Kentucky a_._c Comparison of the Reactions lndueed by Psilocybin _,_,_:, and LSD-25 _ K'an _'• • By _'9'9(_ HARRIS ISBELL ,_. With 1 Figure in the Text _ _ (ReceivedApril 17, 1959) i _fgt_he use of certain intoxicating mushrooms by Indians in Mexico has bb¢_ reviewed by HOFMA_ et al. (1958). V. P. and R. G. WAsso_ (1957) i_ reported the way in which the mushrooms are taken by the Mexican /radOns and the hallucinatory experiences occurring following their lmg_tion. HO_NN et al. (1958a) have described the identification of th_mushrooms and their successful culture by HwrM, and by Hv, nv_and _LEVX. HOFMA_ et al. (1958) isolated a pure compound from the _ooms which had the characteristics of an indoleamine and which b0ntained phosphorus. Later the compound was identified as 0-Phospho- tyl;_-hydroxy-N-dimethyl tryptamine, was synthesized (HoFMANN 1958 ; HOFMA_N et al. 1958a and b) and named psilocybin. Preliminary studies in man (HoF_A_ et al. 1958a) showed that the compound, in d_es of 4 to 8 mg, induced an abnormal mental state resembling that after LSD or mescaline. In animals (C_RLETTI 1958), psilocybin ti/used neurovegetative symptoms although it had no high degree of _tivity on peripheral autonomic structures. The autonomic effects of 'psilocybin seemed to be due to central sympathetic stimulation.
    [Show full text]
  • Making Addiction a Brain Disease: a Social History of Addiction Neuroscience
    Making Addiction a Brain Disease: A Social History of Addiction Neuroscience Nancy D. Campbell, Ph.D. Jerome H. Jaffe . I have fought this issue of “relapsing brain disorder” since somebody decided that this is the current mantra. The model of dependence that we favor is a complex interplay between environment and what may very well be a long- lasting sense of greater sensitivity to drug- related stimuli. Obviously, to the extent that aspects of drug dependence involve learning and changed responsivity to stimuli there are changes in the brain. The Opium Problem (1928) Death in morphin [sic] poisoning is a brain death. The central nervous system is the most severely affected in morphin poisoning. The alterations in this, because of their intensity and regular occurrence, are in the foreground of the pathologico-anatomic picture of poisoning. Death in morphin [sic] poisoning is a brain death. In the most acute form of poisoning, distinct brain alterations are already apparent . a matter of a chronic brain process, which had been going on for some time, overlaid by acute alterations.” W. Weimann, Zur pathologischen Anatomie der akuten und chronischen Morphiumvergiftung, Medezin 1926, v. 8, pp. 205-220; translated and quoted in Terry and Pellens, p. 290. His brain has become addicted, but not his liver The medical interest lies in the fact of the man accustomed to a poison becoming sick. He is sick because the poison taken habitually, while it fixes certain cells and confers on them increased activity or passivity, also renders these or other cells unserviceable for other functions, non-resistant to other influences.
    [Show full text]